Capsule Endoscopy Market Size By Product (Capsule Endoscopes, Systems), By Application (Obscure Gastrointestinal Bleeding (OGIB), Crohn’s Disease, Small Intestine Tumour), By End-Use (Hospitals, Ambulatory Surgery Centers), & Forecast, 2023 – 2032

Capsule Endoscopy Market Size

Capsule Endoscopy Market size was valued at around USD 682.6 million in 2022 and it is estimated to reach over USD 1.6 billion in 2032. Increasing prevalence of gastrointestinal disorders (GI), cancer and other chronic ailments has increased the demand for minimally invasive procedures thereby increasing the adoption of capsule endoscopes.  
 

Moreover, increasing awareness and screening initiatives for early detection and diagnosis of gastrointestinal disorders has fostered the market growth. Governments and healthcare organizations have implemented screening programs, which include capsule endoscopy, to detect conditions like colorectal cancer, lung cancer and Crohn's disease.
 

Technological innovations have played a crucial role in the growth of the capsule endoscopy market. Advancements in image quality, battery life, and software algorithms have enhanced the diagnostic capabilities and user experience of capsule endoscopy devices. Rising healthcare spending for providing better healthcare infrastructure, increasing disposable income and rising government initiatives are some of the major factors responsible for increased adoption of capsule endoscopy globally.
 

Capsule endoscopes are large pill shaped devices installed with lens, light, camera, radio transmitter, and a battery. These devices are used to observe the internal section of the intestines and other parts of the digestive tract.
 

However, high cost of capsule endoscopy procedures can be a significant barrier and impede the capsule endoscopy market growth. The cost of capsule endoscopy includes the equipment, capsules, and associated services, that are relatively expensive. For instance, the cost of capsule endoscope is around USD 1,000 to USD 2,500 and may vary according to the technology incorporated in these devices.
 

Moreover, an average cost of capsule endoscopy can range anywhere from USD 1,500 to USD 3,000. This high cost poses challenges for widespread adoption, particularly in resource-constrained healthcare facilities and regions with limited healthcare budgets These factors can limit the accessibility and affordability, potentially hindering the adoption of capsule endoscopy. Additionally, inadequate reimbursement coverage can deter healthcare providers from offering capsule endoscopy services, impacting market growth.
 

COVID-19 Impact

The recent outbreak of COVID-19 had negatively influenced the capsule endoscopy market revenue, specifically during the initially phase of 2020. The coronavirus outbreak proliferated the disease burden and hampered several global businesses domains including the healthcare sector. During the pandemic, scheduled endoscopic interventions were considered as nonemergent thus, were postponed or delayed. As, these operations require close contact with the patients that may increase the risk of infection to practitioners and other patients. The COVID-19 pandemic has reduced visits to healthcare facilities, causing medical services in several countries to be delayed, including pulmonary and GI endoscopic procedures.
 

However, with the cases being stable in the later stages, in 2021, the capsule endoscopy industry was observed to spike in value and has continued to grow at a substantial pace. Furthermore, as the number of COVID-19 infected patients decreased significantly and several healthcare facilities began delivering healthcare services, gradually returning the procedural volume to pre-pandemic levels.
 

Capsule Endoscopy Market Trends

Increasing prevalence of GI disorders and other chronic ailments has augmented the market growth. The prevalence of GI disorders such as colorectal cancer, Crohn's disease, celiac disease, and gastrointestinal bleeding has been on the rise globally. For instance, according to the European Crohn's and Colitis Organisation (ECCO) data, in 2020, around 2.5 million people in Europe were affected by IBD and is expected to increase in the coming years. These conditions often require thorough examination and evaluation of the GI tract, making capsule endoscopy an effective and minimally invasive diagnostic tool.
 

Additionally, ageing population has increased likelihood of developing chronic diseases, including GI disorders and more susceptible to conditions like colorectal cancer and gastrointestinal bleeding. Capsule endoscopy provides a valuable diagnostic solution for this population, as it is less invasive and better tolerated by older patients.
 

Capsule Endoscopy Market Analysis

Based on products, the capsule endoscopy market is categorized into capsule endoscopes and systems. The capsule endoscopes system is expected to grow at 9.1% CAGR by 2032. This high market growth is owing to several clinical benefits offered by capsule endoscopes in diagnosis and treatment of several chronic ailments. Capsule endoscopes provides a comprehensive visualization of the entire small intestine.
 

Furthermore, technological advancements pertaining to capsule endoscopes such as high image quality, extended battery life and software algorithms have increased the product adoption rate. Capsule endoscopes utilize advanced imaging technologies to capture high-resolution images of the GI tract. These images provide detailed visual information to healthcare professionals for accurate diagnosis and evaluation of conditions such as ulcers, bleeding, tumours, polyps, and inflammatory bowel disease.
 

Based on application, the capsule endoscopy market is divided into obscure gastrointestinal bleeding (OGIB), Crohn’s disease, small intestine tumour and others. Obscure gastrointestinal bleeding (OGIB) is expected to grow reach USD 744.7 million by 2032. This high market share is due increasing prevalence of gastrointestinal bleeding among adult and geriatric population base thereby increasing the adoption of capsule endoscopes.
 

For instance, according to an article published by the American Gastroenterological Association, in 2021, around 311,000 people in the U.S. were estimated to suffer from gastrointestinal bleeding. Capsule endoscopy provides enhanced visualization of the small intestine, which is often the source of OGIB. These devices enable the detection of various lesions and abnormalities that can cause OGIB, such as angiodysplasia, ulcers, tumours, or vascular malformations. Moreover, capsule endoscopy can be used to assess the effectiveness of treatment interventions for OGIB.
 

Based on end-use, the capsule endoscopy market is segmented as hospitals, ambulatory surgical centers, and others. Hospital’s segment held over 48% market share in 2022 and is projected to grow at a robust pace by 2030. This dominant market share is attributed to the increasing use of advanced capsule endoscopy in hospitals, that are projected to increase patient preference for hospitals.
 

Increasing hospitalizations due to medical abnormalities pertaining to gastrointestinal disorders, cancer and other chronic conditions will further augment the market growth. Increasing number of disease screening tests coupled with the availability of highly skilled healthcare professionals are some other attributes that are propelling the growth of the hospitals segment positively. Moreover, the robust healthcare infrastructure and appropriate patient assistance is anticipated to positively impact the segment growth.
 

North America capsule endoscopy marketshare is expected to grow at 8.9% CAGR by 2032. This high market share may be ascribed to a variety of factors, including the presence of significant industry players, an increase in the number of patients suffering from GI disorders, an expanding elderly population, among others. Stomach cancer is one of the leading causes of abdominal pain that leads to capsule endoscopy and is increasingly prevailing among U.S. population.
 

For instance, according to the reports published by the American Cancer Society, in 2021, over 26,000 new stomach cancer patients were reported in the U.S. accounting for more than 11,000 deaths. Moreover, stomach cancer accounts for about 1.5% of all new cancers diagnosed in the U.S. each year. Thus, capsule endoscopy procedures have been significantly rising in the U.S. over the past few years. Presence of prominent market players are engaged in new product development & commercialization leading to overall market growth.
 

Capsule Endoscopy Market Share

Some of the major players operating in the capsule endoscopy industry are:

• Anx Robotica
• CapsoVision Inc 
• Check-Cap Ltd
• Chongqing Jinshan Science and Technology Group Co
• Fujifilm Holding Corporation
• IntroMedic Co
• Medtronic plc
• Olympus Corporation
• RF System lab and Shangxian Minimal Invasive Inc

These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers. These players focus on strategic partnerships, new product launch & commercialization for market expansion.

Capsule Endoscopy Market News:

• In November 2021, Medtronic plc announced that they had received the U.S. FDA 510(k) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures. PillCam SB3 HOME provides a telehealth option for direct visualization and monitoring of the small bowel, to help better detect lesions not detected by upper and lower endoscopy that can indicate Crohn's disease, locate obscure bleeding, etc. This regulatory approval helped the company to enhance their R&D capabilities and increase their product portfolio.
   
• In June 2018, CapsoVision announced a strategic partnership with PENTAX Medical for the distribution of CapsoCam Plus in the U.S. This strategic partnership will help the company to enhance their customer base and increase their business revenue.
   

Capsule endoscopy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million and Units from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Product, 2018 - 2032 (USD Million & Units)

• Capsule Endoscopes
• Colon Capsule Endoscopy
• Esophageal Capsule Endoscopy
• Small Bowel Capsule Endoscopy
• Others

• Systems

By Application, 2018 - 2032 (USD Million)

• Obscure gastrointestinal bleeding (OGIB)
• Crohn’s disease
• Small Intestine Tumor
• Others

By End-use, 2018 - 2032 (USD Million)

• Hospitals
• Ambulatory surgery centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Peru
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Israel
  • Iran